Astellas, Seattle Genetics Break Ground With US ADC Approval
Earlier-Stage Combo Also Shows Big Promise
Executive Summary
Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.
You may also be interested in...
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports